Literature DB >> 4248448

Response of gnotobiotic pigs to Escherichia coli.

O P Miniats, L Mitchell, D A Barnum.   

Abstract

In a study of the response of gnotobiotic pigs to coliform infections, 45 one-week-old germfree pigs were divided into five groups and each group was inoculated orally with a different strain of Escherichia coli. Three of these were enteropathogenic swine strains, P307[08:K87(B), K88 a,b (L):H19]; P570 [0138:K81]; P568[0141:K85a,b(B), K88a,b(L):H4], one was a virulent human strain, H224, [026:K60(B6)], and one was a non-enteropathogenic swine strain, P581[OX13:K68]. It was attempted to protect a portion of the pigs with orally administered specific antisera and sera from non-immunized specific pathogenfree (SPF) pigs. Observations were made on the clinical response, bacterial counts of feces and intestinal contents, gross pathological changes, distribution of the organisms in organs and serum hemagglutinin titers. Infection with E. coli P307 resulted in diarrhea, dehydration and death, unless the pig was protected with specific antiserum. The pigs infected with E. coli P570 had a transient diarrhea but retained their appetites and recovered. Those infected with the other three strains remained healthy throughout. No circulating hemagglutinating antibody against the test strains of E. coli could be detected in any of the pigs seven days or earlier post-inoculation. Relationship could not be established between the numbers of viable E. coli in the feces and the presence of clinical colibacillosis. Orally administered specific antiserum afforded protection against strain P307, but did not reduce the number of E. coli in the gut or alter their distribution in the internal organs. This suggested that the protective effect of specific antibody in the intestine was due to its action on a metabolite (enterotoxin) produced by E. coli P307 rather than the organism itself.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4248448      PMCID: PMC1319503     

Source DB:  PubMed          Journal:  Can J Comp Med        ISSN: 0008-4050


  16 in total

1.  OBSERVATIONS ON THE ALIMENTARY TRACT AND ITS BACTERIAL FLORA IN HEALTHY AND DISEASED PIGS.

Authors:  H W SMITH; J E JONES
Journal:  J Pathol Bacteriol       Date:  1963-10

2.  Enteritis of Early Weaned Pigs: I. Enteropathogenic Escherichia coli.

Authors:  S L Chopra; A C Blackwood; D G Dale
Journal:  Can J Comp Med Vet Sci       Date:  1964-10

3.  Response of gnotobiotic pigs to oral infection with an enteropathogenic and with an edema disease strain of Escherichia coli.

Authors:  O P Miniats
Journal:  Can Vet J       Date:  1970-03       Impact factor: 1.008

4.  Enterotoxic activity of filtrates of escherichia coli in young pigs.

Authors:  E M Kohler
Journal:  Am J Vet Res       Date:  1968-12       Impact factor: 1.156

5.  Observations by the ligated intestinal segment and oral inoculation methods on Escherichia coli infections in pigs, calves, lambs and rabbits.

Authors:  H W Smith; S Halls
Journal:  J Pathol Bacteriol       Date:  1967-04

6.  A study of antibody levels in the young pig.

Authors:  H B Sharpe
Journal:  Res Vet Sci       Date:  1965-10       Impact factor: 2.534

7.  Studies of Escherichia coli in gnotobiotic pigs 3. Evaluation of orally administered specific antisera.

Authors:  E M Kohler; E H Bohl
Journal:  Can J Comp Med Vet Sci       Date:  1966-08

8.  Studies of Escherichia coli in gnotobiotic pigs. I. Experimental reproduction of colibacillosis.

Authors:  E M Kohler; E H Bohl
Journal:  Can J Comp Med Vet Sci       Date:  1966-07

9.  Studies of escherichia coli in gnotobiotic pigs. V. Evaluation of the effects of oral and parenteral administration of immune serum.

Authors:  E M Kohler
Journal:  Can J Comp Med Vet Sci       Date:  1967-11

10.  Escherichia coli associated with colostrum-free neonatal pigs raised in isolation.

Authors:  J G LECCE; B R REEP
Journal:  J Exp Med       Date:  1962-03-01       Impact factor: 14.307

View more
  9 in total

1.  Susceptibility of gnotoibiotic swine to Escherichia coli isolated from nonenteric human infections.

Authors:  R C Meyer; H E Rhoades; J Simon
Journal:  Appl Microbiol       Date:  1972-06

2.  Intestinal antibody secretion in the young pig in response to oral immunization with Escherichia coli.

Authors:  P Porter; R Kenworthy; D E Noakes; W D Allen
Journal:  Immunology       Date:  1974-11       Impact factor: 7.397

3.  The significance of proliferation and enterotoxin production by Escherichia coli in the intestine of gnotobiotic pigs.

Authors:  O P Miniats; C L Gyles
Journal:  Can J Comp Med       Date:  1972-04

Review 4.  Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes.

Authors:  Thomas Clavel; João Carlos Gomes-Neto; Ilias Lagkouvardos; Amanda E Ramer-Tait
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

5.  Polyserositis and arthritis due to Escherichia coli in gnotobiotic pigs.

Authors:  G L Waxler; A L Britt
Journal:  Can J Comp Med       Date:  1972-07

6.  Antibacterial activity of antisera against homologous and heterologous Escherichia coli of porcine origin.

Authors:  C C Enweani; C L Gyles; D A Barnum
Journal:  Can J Comp Med       Date:  1975-01

7.  Experimental colibacillosis in gnotobiotic baby pigs. I. Microbiological and clinical aspects.

Authors:  B R Christie; G L Waxler
Journal:  Can J Comp Med       Date:  1973-07

8.  Pathogenicity of an enterotoxigenic Escherichia coli hemolysin (hlyA) mutant in gnotobiotic piglets.

Authors:  R A Moxley; E M Berberov; D H Francis; J Xing; M Moayeri; R A Welch; D R Baker; R G Barletta
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

9.  Triple and quadruple cervical artery dissections: a systematic review of individual patient data.

Authors:  Valeria Guglielmi; Jeldican Visser; Marcel Arnold; Hakan Sarikaya; René van den Berg; Paul J Nederkoorn; Didier Leys; David Calvet; Manja Kloss; Alessandro Pezzini; Turgut Tatlisumak; Sabrina Schilling; Stéphanie Debette; Jonathan M Coutinho
Journal:  J Neurol       Date:  2019-03-23       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.